Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 10, 2014 - Issue 1
Submit an article Journal homepage
350
Views
24
CrossRef citations to date
0
Altmetric
Reviews

Immunoglobulin class switch recombination deficiency type 1 or CD40 ligand deficiency: from bedside to bench and back again

Armin Hirbod-MobarakehDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran;Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran
,
Asghar AghamohammadiResearch Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
&
Nima RezaeiCorrespondence[email protected]
Pages 91-105 | Published online: 26 Nov 2013

References

  • Davies EG, Thrasher AJ. Update on the hyper immunoglobulin M syndromes. Br. J. Haematol. 149(2), 167–180 (2010).
  • Etzioni A, Ochs HD. The hyper IgM syndrome--an evolving story. Pediatr. Res. 56(4), 519–525 (2004).
  • Hoeger PH, Mayer L. Expansion of a suppressor T-cell population associated with the hyper-IgM syndrome and generalized lymphadenopathy. Clin. Immunol. Immunopathol. 60(1), 118–127 (1991).
  • Renshaw BR, Fanslow WC 3rd, Armitage RJ et al. Humoral immune responses in CD40 ligand-deficient mice. J. Exp. Med. 180(5), 1889–1900 (1994).
  • Erdos M, Durandy A, Marodi L. Genetically acquired class-switch recombination defects: the multi-faced hyper-IgM syndrome. Immunol. Lett. 97(1), 1–6 (2005).
  • Levy J, Espanol-Boren T, Thomas C et al. Clinical spectrum of X-linked hyper-IgM syndrome. J. Pediatr. 131(1 Pt 1), 47–54 (1997).
  • Notarangelo LD, Hayward AR. X-linked immunodeficiency with hyper-IgM (XHIM). Clin. Exp. Immunol. 120(3), 399–405 (2000).
  • Schneider LC. X-linked hyper IgM syndrome. Clin. Rev. Allergy. Immunol. 19(2), 205–215 (2000).
  • Levitt D, Haber P, Rich K, Cooper MD. Hyper IgM immunodeficiency. A primary dysfunction of B lymphocyte isotype switching. J. Clin. Invest. 72(5), 1650–1657 (1983).
  • Piirila H, Valiaho J, Vihinen M. Immunodeficiency mutation databases (IDbases). Hum. Mutat. 27(12), 1200–1208 (2006).
  • Keerthikumar S, Raju R, Kandasamy K et al. RAPID: Resource of Asian Primary Immunodeficiency Diseases. Nucleic Acids Res. 37(Database issue), D863–867 (2009).
  • Allen RC, Armitage RJ, Conley ME et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259(5097), 990–993 (1993).
  • Aruffo A, Farrington M, Hollenbaugh D et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72(2), 291–300 (1993).
  • Korthauer U, Graf D, Mages HW et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 361(6412), 539–541 (1993).
  • Hardy RR, Li YS, Allman D, Asano M, Gui M, Hayakawa K. B-cell commitment, development and selection. Immunol. Rev. 175, 23–32 (2000).
  • Hardy RR, Hayakawa K. B cell development pathways. Annu. Rev. Immunol. 19, 595–621 (2001).
  • Ma YC, Lee WI, Shyur SD, Lin SC, Huang LH, Wu JY. De novo mutation causing X-linked hyper-IgM syndrome: a family study in Taiwan. Asian Pac. J. Allergy Immunol. 23(1), 53–59 (2005).
  • Facchetti F, Appiani C, Salvi L, Levy J, Notarangelo LD. Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immunodeficiency with hyper-IgM. Abortive germinal center cell reaction and severe depletion of follicular dendritic cells. J. Immunol. 154(12), 6624–6633 (1995).
  • Lin SC, Shyur SD, Lee WI, Ma YC, Huang LH. X-linked hyper-immunoglobulin M syndrome: molecular genetic study and long-time follow-up of three generations of a Chinese family. Int. Arch. Allergy Immunol. 140(1), 1–8 (2006).
  • Ochs HD. Patients with abnormal IgM levels: assessment, clinical interpretation, and treatment. Ann. Allergy Asthma Immunol. 100(5), 509–511 (2008).
  • Simon G, Marodi L. [Successful treatment of cyclic neutropenia associated with hyperimmunoglobulin M syndrome using recombinant granulocyte-colony stimulating factor]. Orv. Hetil. 136(40), 2169–2172 (1995).
  • Seyama K, Nonoyama S, Gangsaas I et al. Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. Blood 92(7), 2421–2434 (1998).
  • Tsai HY, Yu HH, Chien YH et al. X-linked hyper-IgM syndrome with CD40LG mutation: two case reports and literature review in Taiwanese patients. J. Microbiol. Immunol. Infect. doi:10.1016/j.jmii.2012.07.004 (2012) ( Epub ahead of print).
  • Seyama K, Kobayashi R, Hasle H et al. Parvovirus B19-induced anemia as the presenting manifestation of X-linked hyper-IgM syndrome. J. Infect. Dis. 178(2), 318–324 (1998).
  • Ostenstad B, Giliani S, Mellbye OJ, Nilsen BR, Abrahamsen T. A boy with X-linked hyper-IgM syndrome and natural killer cell deficiency. Clin. Exp. Immunol. 107(2), 230–234 (1997).
  • Micol R, Kayal S, Mahlaoui N et al. Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia. J. Allergy Clin. Immunol. 129(3), 770–777 (2012).
  • Benesch M, Pfleger A, Eber E, Orth U, Zach MS. Disseminated cytomegalovirus infection as initial manifestation of hyper-IgM syndrome in a 15-month-old boy. Eur. J. Pediatr. 159(6), 453–455 (2000).
  • Lee WI, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood 105(5), 1881–1890 (2005).
  • Winkelstein JA, Marino MC, Ochs H et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 82(6), 373–384 (2003).
  • Antachopoulos C. Invasive fungal infections in congenital immunodeficiencies. Clin. Microbiol. Infect. 16(9), 1335–1342 (2010).
  • Jo EK, Kim HS, Lee MY et al. X-linked hyper-IgM syndrome associated with Cryptosporidium parvum and Cryptococcus neoformans infections: the first case with molecular diagnosis in Korea. J. Korean Med. Sci. 17(1), 116–120 (2002).
  • Milledge J, Kakakios A, Gillis J, Fitzgerald DA. Pneumocystis carinii pneumonia as a presenting feature of X-linked hyper-IgM syndrome. J. Paediatr. Child Health 39(9), 704–706 (2003).
  • Bhatia V, Garg PK, Agarwal V, Sharma M, Ray S. Inflammatory papillary stenosis due to Giardia lamblia in a patient with hyper-immunoglobulin M immunodeficiency syndrome. Gastrointest. Endosc. 66(1), 181–182; discussion 182 (2007).
  • Hayward AR, Levy J, Facchetti F et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J. Immunol. 158(2), 977–983 (1997).
  • Urban C, Benesch M, Sovinz P, Schwinger W, Lackner H. Fatal Evans’ syndrome after matched unrelated donor transplantation for hyper-IgM syndrome. Eur. J. Haematol. 72(6), 444–447 (2004).
  • Dogu F, Cipe FE, Reisli I, Erden E, Ikinciogullari A. CD40 ligand deficiency with grade III liver fibrosis, transplanted by a treosulphan-based conditioning regimen. Exp. Clin. Transplant. 9(5), 349–352 (2011).
  • Aschermann Z, Gomori E, Kovacs GG et al. X-linked hyper-IgM syndrome associated with a rapid course of multifocal leukoencephalopathy. Arch. Neurol. 64(2), 273–276 (2007).
  • Cunningham CK, Bonville CA, Ochs HD et al. Enteroviral meningoencephalitis as a complication of X-linked hyper IgM syndrome. J. Pediatr. 134(5), 584–588 (1999).
  • Bishu S, Madhavan D, Perez P et al. CD40 ligand deficiency: neurologic sequelae with radiographic correlation. Pediatr. Neurol. 41(6), 419–427 (2009).
  • Han GP, Miura K, Ide Y, Tsutsui Y. Genetic analysis of JC virus and BK virus from a patient with progressive multifocal leukoencephalopathy with hyper IgM syndrome. J. Med. Virol. 76(3), 398–405 (2005).
  • Suzuki H, Takahashi Y, Miyajima H. Progressive multifocal leukoencephalopathy complicating X-linked hyper-IgM syndrome in an adult. Intern. Med. 45(20), 1187–1188 (2006).
  • Rodriguez C, Carrion F, Marinovic MA et al. [X-linked hyper-IGM syndrome associated to sclerosing cholangitis and gallbladder neoplasm: clinical case]. Rev. Med. Chil. 131(3), 303–308 (2003).
  • Zirkin HJ, Levy J, Katchko L. Small cell undifferentiated carcinoma of the colon associated with hepatocellular carcinoma in an immunodeficient patient. Hum. Pathol. 27(9), 992–996 (1996).
  • Malhotra RK, Li W. Poorly differentiated gastroenteropancreatic neuroendocrine carcinoma associated with X-linked hyperimmunoglobulin M syndrome. Arch. Pathol. Lab. Med. 132(5), 847–850 (2008).
  • Gallerani I, Innocenti DD, Coronella G et al. Cutaneous sarcoid-like granulomas in a patient with X-linked hyper-IgM syndrome. Pediatr. Dermatol. 21(1), 39–43 (2004).
  • Nagasawa M, Itoh S, Sawada Y, Morio T, Nonoyama S, Mizutani S. Coagulopathy in a patient with X-linked hyper-IgM syndrome who developed Kaposi’s sarcoma. Am. J. Hematol. 75(2), 116–117 (2004).
  • Nagaraj N, Egwim C, Adler DG. X-linked hyper-IgM syndrome associated with poorly differentiated neuroendocrine tumor presenting as obstructive jaundice secondary to extensive adenopathy. Dig. Dis. Sci. 52(9), 2312–2316 (2007).
  • Immunodeficiency and Cancer (3rd Edition). Filipovich LGT ( Ed.). Elsevier/Churchill Livingstone, London, UK (2004).
  • Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J. Clin. Immunol. 28( Suppl. 1), S62–S66 (2008).
  • Schuster A, Apfelstedt-Sylla E, Pusch CM, Zrenner E, Thirkill CE. Autoimmune retinopathy with RPE hypersensitivity and ‘negative ERG’ in X-linked hyper-IgM syndrome. Ocul. Immunol. Inflamm. 13(2–3), 235–243 (2005).
  • Lacroix-Desmazes S, Resnick I et al. Defective self-reactive antibody repertoire of serum IgM in patients with hyper-IgM syndrome. J. Immunol. 162(9), 5601–5608 (1999).
  • Gulino AV, Notarangelo LD. Hyper IgM syndromes. Curr. Opin. Rheumatol. 15(4), 422–429 (2003).
  • Lopez-Granados E, Temmerman ST, Wu L et al. Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proc. Natl Acad. Sci. USA 104(12), 5056–5061 (2007).
  • Webster EA, Khakoo AY, Mackus WJ et al. An aggressive form of polyarticular arthritis in a man with CD154 mutation (X-linked hyper-IgM syndrome). Arthritis Rheum. 42(6), 1291–1296 (1999).
  • Callard RE, Armitage RJ, Fanslow WC, Spriggs MK. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol. Today 14(11), 559–564 (1993).
  • Karpusas M, Hsu YM, Wang JH et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure 3(12), 1426 (1995).
  • Hollenbaugh D, Wu LH, Ochs HD et al. The random inactivation of the X chromosome carrying the defective gene responsible for X-linked hyper IgM syndrome (X-HIM) in female carriers of HIGM1. J. Clin. Invest. 94(2), 616–622 (1994).
  • Hollenbaugh D, Grosmaire LS, Kullas CD et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J. 11(12), 4313–4321 (1992).
  • Shimadzu M, Nunoi H, Terasaki H et al. Structural organization of the gene for CD40 ligand: molecular analysis for diagnosis of X-linked hyper-IgM syndrome. Biochim. Biophys. Acta 1260(1), 67–72 (1995).
  • Garber E, Su L, Ehrenfels B, Karpusas M, Hsu YM. CD154 variants associated with hyper-IgM syndrome can form oligomers and trigger CD40-mediated signals. J. Biol. Chem. 274(47), 33545–33550 (1999).
  • Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol. Life Sci. 58(1), 4–43 (2001).
  • van Kooten C, Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 67(1), 2–17 (2000).
  • Subauste CS, Wessendarp M, Sorensen RU, Leiva LE. CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer. J. Immunol. 162(11), 6690–6700 (1999).
  • Sipsas NV, Sfikakis PP, Kontos A, Kordossis T. Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4(+) T-cell counts. Clin. Diagn. Lab. Immunol. 9(3), 558–561 (2002).
  • Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe? Immunol. Res. 16(1), 59–70 (1997).
  • Leveille C, Bouillon M, Guo W et al. CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling. J. Biol. Chem. 282(8), 5143–5151 (2007).
  • Singh J, Garber E, Van Vlijmen H et al. The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci. 7(5), 1124–1135 (1998).
  • Ochs HD, Hollenbaugh D, Aruffo A. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Semin. Immunol. 6(5), 337–341 (1994).
  • Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. Nat. Rev. Immunol. 13(7), 519–533 (2013).
  • Durandy A, Peron S, Fischer A. Hyper-IgM syndromes. Curr. Opin. Rheumatol. 18(4), 369–376 (2006).
  • Herve M, Isnardi I, Ng YS et al. CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J. Exp. Med. 204(7), 1583–1593 (2007).
  • Cron RQ. CD154 transcriptional regulation in primary human CD4 T cells. Immunol. Res. 27(2–3), 185–202 (2003).
  • Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl Acad. Sci. USA 92(10), 4342–4346 (1995).
  • Longo NS, Lugar PL, Yavuz S et al. Analysis of somatic hypermutation in X-linked hyper-IgM syndrome shows specific deficiencies in mutational targeting. Blood 113(16), 3706–3715 (2009).
  • Brezinschek HP, Dorner T, Monson NL, Brezinschek RI, Lipsky PE. The influence of CD40-CD154 interactions on the expressed human V(H) repertoire: analysis of V(H) genes expressed by individual B cells of a patient with X-linked hyper-IgM syndrome. Int. Immunol. 12(6), 767–775 (2000).
  • Jelinek DF, Lipsky PE. Comparative activation requirements of human peripheral blood, spleen, and lymph node B cells. J. Immunol. 139(4), 1005–1013 (1987).
  • Pascual V, Capra JD. Human immunoglobulin heavy-chain variable region genes: organization, polymorphism, and expression. Adv. Immunol. 49, 1–74 (1991).
  • Weller S, Faili A, Garcia C et al. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc. Natl Acad. Sci. USA 98(3), 1166–1170 (2001).
  • Durandy A. Hyper-IgM syndromes: a model for studying the regulation of class switch recombination and somatic hypermutation generation. Biochem. Soc. Trans. 30(4), 815–818 (2002).
  • Mavroudi I, Papadaki V, Pyrovolaki K, Katonis P, Eliopoulos AG, Papadaki HA. The CD40/CD40 ligand interactions exert pleiotropic effects on bone marrow granulopoiesis. J. Leukoc. Biol. 89(5), 771–783 (2011).
  • Mavroudi I, Papadaki HA. The role of CD40/CD40 ligand interactions in bone marrow granulopoiesis. ScientificWorldJournal 11, 671453 (2011).
  • Scott MJ, Hoth JJ, Stagner MK, Gardner SA, Peyton JC, Cheadle WG. CD40-CD154 interactions between macrophages and natural killer cells during sepsis are critical for macrophage activation and are not interferon gamma dependent. Clin. Exp. Immunol. 137(3), 469–477 (2004).
  • Atochina O, Harn D. LNFPIII/LeX-stimulated macrophages activate natural killer cells via CD40-CD40L interaction. Clin. Diagn. Lab. Immunol. 12(9), 1041–1049 (2005).
  • El Fakhry Y, Alturaihi H, Yacoub D et al. Functional interaction of CD154 protein with alpha5beta1 integrin is totally independent from its binding to alphaIIbbeta3 integrin and CD40 molecules. J. Biol. Chem. 287(22), 18055–18066 (2012).
  • Clarke SR. The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity. J. Leukoc. Biol. 67(5), 607–614 (2000).
  • Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111–135 (1998).
  • Soong L, Xu JC, Grewal IS et al. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4(3), 263–273 (1996).
  • Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 4(3), 283–289 (1996).
  • Chirmule N, Tazelaar J, Wilson JM. Th2-dependent B cell responses in the absence of CD40-CD40 ligand interactions. J. Immunol. 164(1), 248–255 (2000).
  • Kumanogoh A, Wang X, Lee I et al. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J. Immunol. 166(1), 353–360 (2001).
  • Hernandez MG, Shen L, Rock KL. CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4+ T cell help. J. Immunol. 178(5), 2844–2852 (2007).
  • Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22, 307–328 (2004).
  • Howland KC, Ausubel LJ, London CA, Abbas AK. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J. Immunol. 164(9), 4465–4470 (2000).
  • Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ. CD40–CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin. Immunol. 10(6), 443–448 (1998).
  • Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297(5589), 2060–2063 (2002).
  • Campos-Neto A, Ovendale P, Bement T et al. CD40 ligand is not essential for the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis. J. Immunol. 160(5), 2037–2041 (1998).
  • Bachmann MF, Schwarz K, Wolint P et al. Cutting edge: distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8+ T cells. J. Immunol. 173(4), 2217–2221 (2004).
  • Bhadra R, Gigley JP, Khan IA. Cutting edge: CD40-CD40 ligand pathway plays a critical CD8-intrinsic and -extrinsic role during rescue of exhausted CD8 T cells. J. Immunol. 187(9), 4421–4425 (2011).
  • Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J. Immunol. 172(4), 2011–2015 (2004).
  • Murugaiyan G, Agrawal R, Mishra GC, Mitra D, Saha B. Differential CD40/CD40L expression results in counteracting antitumor immune responses. J. Immunol. 178(4), 2047–2055 (2007).
  • Sitati E, McCandless EE, Klein RS, Diamond MS. CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis. J. Virol. 81(18), 9801–9811 (2007).
  • Schiemann B, Gommerman JL, Vora K et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293(5537), 2111–2114 (2001).
  • Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 301(5638), 1374–1377 (2003).
  • Cuss SM, Green EA. Abrogation of CD40-CD154 signaling impedes the homeostasis of thymic resident regulatory T cells by altering the levels of IL-2, but does not affect regulatory T cell development. J. Immunol. 189(4), 1717–1725 (2012).
  • Guiducci C, Valzasina B, Dislich H, Colombo MP. CD40/CD40L interaction regulates CD4+CD25+ Treg homeostasis through dendritic cell-produced IL-2. Eur. J. Immunol. 35(2), 557–567 (2005).
  • Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr. Opin. Rheumatol. 15(4), 430–435 (2003).
  • Cunningham-Rundles C. Autoimmunity in primary immune deficiency: taking lessons from our patients. Clin. Exp. Immunol. 164( Suppl. 2), 6–11 (2011).
  • Etzioni A. Immune deficiency and autoimmunity. Autoimmun. Rev. 2(6), 364–369 (2003).
  • Bussone G, Mouthon L. Autoimmune manifestations in primary immune deficiencies. Autoimmun. Rev. 8(4), 332–336 (2009).
  • Goyal R, Bulua AC, Nikolov NP, Schwartzberg PL, Siegel RM. Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders. Curr. Opin. Rheumatol. 21(1), 78–84 (2009).
  • Devergne O, Hatzivassiliou E, Izumi KM et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol. Cell Biol. 16(12), 7098–7108 (1996).
  • Takayanagi H, Ogasawara K, Hida S et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408(6812), 600–605 (2000).
  • Takayanagi H, Kim S, Taniguchi T. Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis. Res. 4( Suppl. 3), S227–S232 (2002).
  • Feng X. RANKing intracellular signaling in osteoclasts. IUBMB Life 57(6), 389–395 (2005).
  • Scholl PR, O’Gorman MR, Pachman LM, Haut P, Kletzel M. Correction of neutropenia and hypogammaglobulinemia in X-linked hyper-IgM syndrome by allogeneic bone marrow transplantation. Bone Marrow Transplant. 22(12), 1215–1218 (1998).
  • Seyama K, Kira S, Ishidoh K, Souma S, Miyakawa T, Kominami E. Genomic structure and PCR-SSCP analysis of the human CD40 ligand gene: its application to prenatal screening for X-linked hyper-IgM syndrome. Hum. Genet. 97(2), 180–185 (1996).
  • Jayoussi-Assalia R, Etzioni A, Notarangelo LD et al. Prenatal diagnosis of X-linked hyper-IGM syndrome by direct detection of mutation Q220X in the CD40L gene using PCR-mediated site directed mutagenesis. Prenat. Diagn. 20(10), 822–823 (2000).
  • DiSanto JP, Markiewicz S, Gauchat JF, Bonnefoy JY, Fischer A, de Saint Basile G. Brief report: prenatal diagnosis of X-linked hyper-IgM syndrome. N. Engl. J. Med. 330(14), 969–973 (1994).
  • Kato T, Tsuge I, Inaba J, Kato K, Matsuyama T, Kojima S. Successful bone marrow transplantation in a child with X-linked hyper-IgM syndrome. Bone Marrow Transplant. 23(10), 1081–1083 (1999).
  • Duplantier JE, Seyama K, Day NK et al. Immunologic reconstitution following bone marrow transplantation for X-linked hyper IgM syndrome. Clin. Immunol. 98(3), 313–318 (2001).
  • Hadzic N, Pagliuca A, Rela M et al. Correction of the hyper-IgM syndrome after liver and bone marrow transplantation. N. Engl. J. Med. 342(5), 320–324 (2000).
  • Isam H, Al-Wahadneh A. Successful bone marrow transplantation in a child with X-linked hyper-IgM syndrome. Saudi J. Kidney Dis. Transpl. 15(4), 489–493 (2004).
  • Tomizawa D, Imai K, Ito S et al. Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience. Am. J. Hematol. 76(1), 33–39 (2004).
  • Dimicoli S, Bensoussan D, Latger-Cannard V et al. Complete recovery from Cryptosporidium parvum infection with gastroenteritis and sclerosing cholangitis after successful bone marrow transplantation in two brothers with X-linked hyper-IgM syndrome. Bone Marrow Transplant. 32(7), 733–737 (2003).
  • Leone V, Tommasini A, Andolina M et al. Elective bone marrow transplantation in a child with X-linked hyper-IgM syndrome presenting with acute respiratory distress syndrome. Bone Marrow Transplant. 30(1), 49–52 (2002).
  • Jain A, Kovacs JA, Nelson DL et al. Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand. Blood 118(14), 3811–3817 (2011).
  • Fan X, Upadhyaya B, Wu L et al. CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome. Clin. Immunol. 143(2), 152–161 (2012).
  • Brown MP, Topham DJ, Sangster MY et al. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat. Med. 4(11), 1253–1260 (1998).
  • Romero Z, Torres S, Cobo M et al. A tissue-specific, activation-inducible, lentiviral vector regulated by human CD40L proximal promoter sequences. Gene Ther. 18(4), 364–371 (2011).
  • Blaeser F, Kelly M, Siegrist K et al. Critical function of the CD40 pathway in parvovirus B19 infection revealed by a hypomorphic CD40 ligand mutation. Clin. Immunol. 117(3), 231–237 (2005).
  • Danielian S, Oleastro M, Eva Rivas M, Cantisano C, Zelazko M. Clinical follow-up of 11 Argentinian CD40L-deficient patients with 7 unique mutations including the so-called “milder” mutants. J. Clin. Immunol. 27(4), 455–459 (2007).
  • Aghamohammadi A, Parvaneh N, Rezaei N et al. Clinical and laboratory findings in hyper-IgM syndrome with novel CD40L and AICDA mutations. J. Clin. Immunol. 29(6), 769–776 (2009).
  • Nonoyama S, Shimadzu M, Toru H et al. Mutations of the CD40 ligand gene in 13 Japanese patients with X-linked hyper-IgM syndrome. Hum. Genet. 99(5), 624–627 (1997).
  • Katz F, Hinshelwood S, Rutland P, Jones A, Kinnon C, Morgan G. Mutation analysis in CD40 ligand deficiency leading to X-linked hypogammaglobulinemia with hyper IgM syndrome. Hum. Mutat. 8(3), 223–228 (1996).
  • Macchi P, Villa A, Strina D et al. Characterization of nine novel mutations in the CD40 ligand gene in patients with X-linked hyper IgM syndrome of various ancestry. Am. J. Hum. Genet. 56(4), 898–906 (1995).
  • Gilmour KC, Walshe D, Heath S et al. Immunological and genetic analysis of 65 patients with a clinical suspicion of X linked hyper-IgM. Mol. Pathol. 56(5), 256–262 (2003).
  • Rangel-Santos A, Wakim VL, Jacob CM et al. Molecular characterization of patients with X-linked Hyper-IgM syndrome: description of two novel CD40L mutations. Scand. J. Immunol. 69(2), 169–173 (2009).
  • Kraakman ME, de Weers M, Espanol T, Schuurman RK, Hendriks RW. Identification of a CD40L gene mutation and genetic counselling in a family with immunodeficiency with hyperimmunoglobulinemia M. Clin. Genet. 48(1), 46–48 (1995).
  • Lin Q, Rohrer J, Allen RC et al. A single strand conformation polymorphism study of CD40 ligand. Efficient mutation analysis and carrier detection for X-linked hyper IgM syndrome. J. Clin. Invest. 97(1), 196–201 (1996).
  • Erdos M, Lakos G, Derfalvi B, Notarangelo LD, Durandy A, Marodi L. Molecular genetic analysis of Hungarian patients with the hyper-immunoglobulin M syndrome. Mol. Immunol. 45(1), 278–282 (2008).
  • Prasad ML, Velickovic M, Weston SA, Benson EM. Mutational screening of the CD40 ligand (CD40L) gene in patients with X linked hyper-IgM syndrome (XHIM) and determination of carrier status in female relatives. J. Clin. Pathol. 58(1), 90–92 (2005).
  • Garcia-Perez MA, Paz-Artal E, Corell A et al. Mutations of CD40 ligand in two patients with hyper-IgM syndrome. Immunobiology 207(4), 285–294 (2003).
  • Kroczek RA, Graf D, Brugnoni D et al. Defective expression of CD40 ligand on T cells causes “X-linked immunodeficiency with hyper-IgM (HIGM1)”. Immunol. Rev. 138, 39–59 (1994).
  • Iseki M, Anzo M, Yamashita N, Matsuo N. Hyper-IgM immunodeficiency with disseminated cryptococcosis. Acta Paediatr. 83(7), 780–782 (1994).
  • Saiki O, Tanaka T, Wada Y et al. Signaling through CD40 rescues IgE but not IgG or IgA secretion in X-linked immunodeficiency with hyper-IgM. J. Clin. Invest. 95(2), 510–514 (1995).
  • Lin SC, Shyur SD, Ma YC, Huang LH, Lee WI. Hyper-IgM1 syndrome with interstitial pneumonia and diarrhea caused by coxsackievirus B4 in a 3-month-old infant. Ann. Allergy Asthma Immunol. 95(1), 93–97 (2005).
  • Hsu AP, Fleisher TA, Niemela JE. Mutation analysis in primary immunodeficiency diseases: case studies. Curr. Opin. Allergy Clin. Immunol. 9(6), 517–524 (2009).
  • Andrews FJ, Katz F, Jones A, Smith S, Finn A. CD40 ligand deficiency presenting as unresponsive neutropenia. Arch. Dis. Child. 74(5), 458–459 (1996).
  • Lopez-Granados E, Cambronero R, Ferreira A, Fontan G, Garcia-Rodriguez MC. Three novel mutations reflect the variety of defects causing phenotypically diverse X-linked hyper-IgM syndrome. Clin. Exp. Immunol. 133(1), 123–131 (2003).
  • Van Hoeyveld E, Zhang PX, De Boeck K, Fuleihan R, Bossuyt X. Hyper-immunoglobulin M syndrome caused by a mutation in the promotor for CD40L. Immunology 120(4), 497–501 (2007).
  • DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 361(6412), 541–543 (1993).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.